Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension

Basit Öğe Kaydı
dc.contributor.authorBulur, Serkan
dc.contributor.authorÖzhan, Hakan
dc.contributor.authorErden, İsmail
dc.contributor.authorAlemdar, Recai
dc.contributor.authorAydın, Mesut
dc.contributor.authorÇağlar, Onur
dc.contributor.authorOrdu, Serkan
dc.date.accessioned2020-05-01T09:12:08Z
dc.date.available2020-05-01T09:12:08Z
dc.date.issued2011
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionWOS: 000285544300006en_US
dc.descriptionPubMed: 20975532en_US
dc.description.abstractThe efficacy of olmesartan on fibrinolytic capacity has not been studied yet. Therefore, the aim of the present study was to investigate the efficacy of olmesartan on hemostatic/fibrinolytic status by measuring plasma level of plasminogen activator inhibitor-1 (PAI-1) and soluble thrombomodulin levels in patients with hypertension. Forty-two consecutive, newly diagnosed (25 women and 17 men with a mean age of 48 +/- 8 years) patients with untreated essential hypertension were included in the study. Olmesartan medoxomil (20 mg/day) was started and the patients were followed up for 6 months. Baseline biochemical variables, thrombomodulin, and PAI-1 levels were compared with the levels of these variables measured at the end of the 6-month follow-up period. After 6 months of treatment with olmesartan medoxomil, there was a significant reduction in systolic and diastolic blood pressure (from 159.5 +/- 10.9 to 134.6 +/- 12.7 mmHg and from 98.0 +/- 6.3 to 83.9 +/- 7.0 mmHg, respectively). Mean plasma PAI-1 and thrombomodulin levels were also significantly decreased (59.73 +/- 41.91 vs. 48.60 +/- 33.65 ng/ml, P=0.001 and 8.09 +/- 2.29 vs. 6.92 +/- 1.42 mu g/l, P<0.001, respectively). Olmesartan medoxomil decreased plasma PAI-1 and thrombomodulin levels after 6 months of therapy, indicating a favorable effect on fibrinolytic capacity in patients with essential hypertension. Blood Coagul Fibrinolysis 22:29-33 (C) 2011 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.en_US
dc.identifier.doi10.1097/MBC.0b013e328340aecfen_US
dc.identifier.endpage33en_US
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage29en_US
dc.identifier.urihttps://doi.org/10.1097/MBC.0b013e328340aecf
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5885
dc.identifier.volume22en_US
dc.identifier.wosWOS:000285544300006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofBlood Coagulation & Fibrinolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectfibrinolytic capacityen_US
dc.subjecthypertensionen_US
dc.subjectolmesartanen_US
dc.titleEfficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertensionen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5885.pdf
Boyut:
232.54 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu